Lyra Therapeutics（纳斯达克股票代码：LYRA）报告的季度每股亏损为$(1.43)，低于分析师一致预期的$(1.38)，相差3.62%。与去年同期每股亏损$(1.26)相比，下降了13.49%。公司报告的季度销售额为$1.534百万，超过分析师一致预期的$1.524百万，相差0.69%。与去年同期销售额$1.558百万相比，下降了1.54%。

以上内容来自Benzinga Earnings专栏，原文如下：

Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(1.43) per share which missed the analyst consensus estimate of $(1.38) by 3.62 percent. This is a 13.49 percent decrease over losses of $(1.26) per share from the same period last year. The company reported quarterly sales of $1.534 million which beat the analyst consensus estimate of $1.524 million by 0.69 percent. This is a 1.54 percent decrease over sales of $1.558 million the same period last year.